Program
mocravimod
Also written as “KRP-203”, “Study Part 1: KRP203” and “Study Part 2: KRP203 lower dose”.
Its studies are mostly in Leukemia, Myeloid, Acute · Hematologic Neoplasms · Colitis, Ulcerative · Lupus Erythematosus, Cutaneous, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novartis | 30 open or running | phase 2since Feb 10, 2011 | Feb 10, 2011 | none ahead |
| Priothera SAS | 21 open or running | phase 3since Jun 17, 2022 | Jun 17, 2022 | May 2027phase 3 · NCT05429632 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 10, 2011First study: phase 2 study in Lupus Erythematosus, CutaneousNew to NovartisNovartis · NCT01294774 · 10 enrolled · Germany, Greece, Italy
- May 12, 2011Phase 2 study in Colitis, UlcerativeNovartis · NCT01375179 · 27 enrolled · Belgium, Germany, Hungary and more
- Apr 9, 2013Phase 1 study in Hematologic NeoplasmsNovartis · NCT01830010 · 23 enrolled · France, Germany, Switzerland
- Jun 17, 2022Priothera SAS's first study: phase 3 study in Leukemia, Myeloid, AcuteNew to Priothera SASPriothera SAS · NCT05429632 · 366 planned · United States, Argentina, Brazil and more
- Oct 7, 2026Phase 1 study in Healthy VollunteerPriothera SAS · NCT07937046 · 64 enrolled
Ahead
- May 2027Primary completion: phase 3 study in Leukemia, Myeloid, AcutePriothera SAS · NCT05429632
TargetBeta
“The hydrochloride salt form of mocravimod, a sphingosine 1-phosphate (S1P) receptor agonist, ”NCIt, by rule
“Sphingosine 1-phosphate receptor Edg-1 agonist”ChEMBL 37, by rule
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07937046Healthy Vollunteer | 1 | Completed | Priothera SAS | May 16, 2011 | 64 |
| NCT05429632Leukemia, Myeloid, Acute · United States, Argentina, Brazil and more | 3 | Recruiting | Priothera SAS | May 2027 | 366 |
| NCT01830010Hematologic Neoplasms · France, Germany, Switzerland | 1 | Completed | Novartis | Aug 21, 2018 | 23 |
| NCT01375179Colitis, Ulcerative · Belgium, Germany, Hungary and more | 2 | Terminated | Novartis | May 2012 | 27 |
| NCT01294774Lupus Erythematosus, Cutaneous · Germany, Greece, Italy | 2 | Completed | Novartis | Oct 2012 | 10 |
How it is read
Names in the registry
- “KRP-203”, 1 entry
- “mocravimod”, 1 entry
- “Study Part 1: KRP203”, 1 entry
- “Study Part 2: KRP203 lower dose”, 1 entry
- “Study Part 2: KRP203 higher dose”, 1 entry
Codes read as this program: KRP203.
Conditions, from the studies’ own filings
- Leukemia, Myeloid, Acute, 1 study
- Hematologic Neoplasms, 1 study
- Colitis, Ulcerative, 1 study
- Lupus Erythematosus, Cutaneous, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.